| Ranbaxy recalls drug in US | 20-NOV-09 |
|
| India’s leading drug maker Ranbaxy has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’. |
|
|
|
| Ranbaxy finding ways to make two of four acquisitions work | 16-NOV-09 |
|
| The key strategic investments made by the erstwhile promoters of Ranbaxy Laboratories may seem to be floundering on the surface, but the Daiichi-owned company is looking at bigger engagements with at least two of these companies. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Not the right medicine | 03-NOV-09 |
|
| The Indian Pharmaceutical Alliance, which represents a large section of the country’s pharmaceutical companies, has taken the rather unusual step of asking the government to come to the aid of the industry, which has seen a string of foreign acquisitions of Indian players. None of these acquisitions is hostile. So, where does the government come in, particularly when there is no security issue at stake? It is also quite clear that some of these deals, like the most celebrated one of Ranbaxy going to its Japanese acquirer Daiichi Sankyo, have been very attractively priced. So, the industry has been doing quite well and managements have been able to exit at a premium. If the industry were in trouble and, therefore, needing government assistance, the scenario would have been different. |
|
|
|
| New tonic for Revital | 02-NOV-09 |
|
| Yuvraj Singh has just told us the secret of his power-packed performances. It’s Revital, a combination of vitamin, mineral and the Chinese wonder herb Ginseng. |
|
|
|
| Ranbaxy-Daiichi working on 3-yr plan for synergy | 28-OCT-09 |
|
| Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo are working on a three-year plan for exploiting synergies in operations to enhance their generic as well as branded business across the globe. |
|
|
|
| Ranbaxy Labs reports net profit of Rs 116 cr | 27-OCT-09 |
|
| India’s biggest drug maker, Ranbaxy Laboratories, has posted a net profit of Rs 116.6 crore for its third quarter ended September, against a net loss of Rs 394.5 crore in the same period last year, which had been largely attributed to mark-to-market exchange losses. |
|
|
|
|
|
|
| Ranbaxy Q3 net profit at Rs 186 cr | 26-OCT-09 |
|
| Ranbaxy Laboratories recorded a net profit of Rs 186.08 crore during the quarter ended September 30, 2009 as against a net loss of Rs 352.93 crore during the corresponding period last year. |
|
|
|
| Bhupesh Bhandari: The new pharmaceutical order | 23-OCT-09 |
|
| The original poster boys of the Indian pharmaceutical industry all seem to be in a spot of bother. Habil Khorakiwala of Wockhardt has sold his animal health, nutrition and hospital businesses to repay the debt on his books. Dilip Shanhgvi of Sun Pharma faces regulatory problems in the US. Caraco Pharmaceuticals, a company he owns in that country, faces a manufacturing ban imposed by the Food & Drug Administration. Dr Reddy’s Laboratories has had to recall products in the US. |
|
|
|
| Ranbaxy cheers court win, ends flat | 17-OCT-09 |
|
| The stock slipped further to a low of Rs 390 - down 2.5% from the day's high. The stock finally ended flat at Rs 392. Around 97,333 shares changed hands at the counter today. |
|
|
|
Content Guide
